Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21
Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.
Stocks · News reference
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.
Raymond James Upgrades Sabra Health Care REIT to Market Perform
Raymond James analyst David Rodgers upgrades Sabra Health Care REIT (NASDAQ:SBRA) from Underperform to Market Perform.